Venetoclax for Chronic Lymphocytic Leukaemia Progressing after Ibrutinib: a Multicentre, Open-Label Phase 2 Trial

BACKGROUND: Therapy targeting Bruton’s tyrosine kinase (BTK) with ibrutinib has transformed treatment for chronic lymphocytic leukaemia (CLL). Patients who are refractory or relapse after ibrutinib experience poor outcomes. Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 that has a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Lancet Oncol
Главные авторы: Jones, Jeffrey A., Mato, Anthony R., Wierda, William G., Davids, Matthew S., Choi, Michael, Cheson, Bruce D., Furman, Richard R., Lamanna, Nicole, Barr, Paul M., Zhou, Lang, Chyla, Brenda, Salem, Ahmed Hamed, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Coutre, Steven, Woyach, Jennifer, Byrd, John C.
Формат: Artigo
Язык:Inglês
Опубликовано: 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6027999/
https://ncbi.nlm.nih.gov/pubmed/29246803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30909-9
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы